Dermatology
Skin clinical trials
Psoriasis, eczema, skin cancers, and other conditions of the skin and connective tissue. We’re tracking 5,032 recruiting studies in this area right now.
By phase
- Not applicable2,815
- Phase 2751
- Phase 1525
- Phase 3381
- Phase 1/Phase 2297
- Phase 4204
- Phase 2/Phase 359
Top conditions
- Breast Cancer1,197
- Melanoma174
- Metastatic Breast Cancer138
- Rheumatoid Arthritis131
- Atopic Dermatitis122
- Systemic Lupus Erythematosus121
- Breast Neoplasms111
- Triple Negative Breast Cancer110
- Colorectal Cancer95
- Ovarian Cancer91
- Psoriasis85
- Breast Carcinoma79
- Lung Cancer77
- Prostate Cancer70
- Rheumatoid Arthritis (RA)68
- Diabetic Foot Ulcer60
- Cancer58
- Systemic Lupus Erythematosus (SLE)52
Leading sponsors
- Fudan University64
- M.D. Anderson Cancer Center51
- Memorial Sloan Kettering Cancer Center49
- Novartis Pharmaceuticals48
- Mayo Clinic40
- AstraZeneca38
- Assistance Publique - Hôpitaux de Paris37
- National Cancer Institute (NCI)37
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University34
- Second Affiliated Hospital, Zhejiang University, School of Medicine30
Where studies are running
- California406
- Arizona150
- Alabama130
- Florida128
- New York110
- Texas106
- Maryland94
- Massachusetts86
- Pennsylvania72
- North Carolina68
Recruiting studies5,032 total
- NCT05372640RecruitingPhase 1
Drug combo trial for rare cancers with shared NUT features
This Phase 1 trial tests the safety and early signs of effectiveness of combining two anti-cancer drugs (ZEN003694 and abemaciclib) in teens and adults with metastatic or unresectable NUT carcinoma, breast cancer, and other solid tumors. It may help by finding a safer dose and whether the drug combination can shrink or control tumors that do not respond to standard treatments.
Los Angeles, CaliforniaAges 12 years+ - NCT05377996RecruitingPhase 1/Phase 2
Study drug for advanced solid tumors with tumor tissue testing
This early-stage study tests emiltatug leda-dotin (Emi-Le) in people with advanced or recurring solid cancers. It aims to see how the drug works and how safely it can be given, using tumor tissue testing to help understand who may benefit.
Phoenix, ArizonaAges 18 years+ - NCT05366881Recruiting
Blood test study to spot early cancer signal and cancer leftovers
This observational study checks whether a blood test (a “cfDNA” test) can detect early signs of cancer or small amounts of cancer left after treatment. It may help doctors use a simple blood sample to improve cancer detection and follow-up.
Duarte, CaliforniaAges 40 years+ - NCT05386108RecruitingPhase 1/Phase 2
Test abemaciclib plus elacestrant for breast cancer brain spread
This trial studies whether the combination of abemaciclib and elacestrant can slow or shrink ER-positive, HER2-negative breast cancer that has spread to the brain. It is designed for people whose cancer has progressed despite prior hormone (endocrine) treatment.
Fullerton, CaliforniaAges 18 years+ - NCT05396105Enrolling by invitationPhase 2/Phase 3
Oral PHA-022121 extension for hereditary angioedema attacks
This study is an extension trial of an oral medicine (PHA-022121) for treating acute attacks in people with hereditary angioedema (HAE), especially HAE type III (HAE-nC1INH). It checks whether continuing this oral treatment can safely help manage attacks after you’ve taken it before.
Birmingham, AlabamaAges 12 years+ - NCT05379985RecruitingPhase 1/Phase 2
Test drug RMC-6236 for certain RAS mutations in advanced cancers
This trial tests whether RMC-6236 can treat advanced solid tumors that have specific RAS-related gene changes (especially certain KRAS G12 mutations). You may be able to join if your tumor’s DNA test shows the right mutation and your overall health is good enough for study visits.
Orange, CaliforniaAges 18 years+ - NCT05377047RecruitingPhase 3
High-precision radiation for limited breast cancer spread
This trial tests a high-precision radiation therapy (called stereotactic ablative radiotherapy) to treat breast cancer that has spread to a limited number of spots in the body. It aims to control the cancer and improve outcomes, and you can join while on your first-line systemic treatment if the cancer is stable.
CorkAges 18 years+ - NCT05368038Enrolling by invitation
Newborn screening program for babies up to 4 weeks old
This trial tests a flexible newborn screening process that looks for certain conditions early in life. It may help by catching problems sooner, when treatment can be started earlier.
Brooklyn, New YorkAges Up to 4 weeks - NCT05377905RecruitingPhase 1/Phase 2
Microneedle skin treatment plus doxorubicin for skin cancer
This early-phase study tests whether delivering chemotherapy through tiny skin needles (microneedles) can shrink or control cutaneous squamous cell cancer (cSCC) that can be surgically treated. Because it’s Phase 1/2, the main goals are to check safety and find the best way to deliver the treatment.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05373823Recruiting
Online skin check coaching for melanoma survivors
This study tests an online program to help melanoma survivors do full-body skin self-checks regularly. It may help you catch new or changing skin areas earlier by improving how often and how thoroughly you check.
New Brunswick, New JerseyAges 18 years+ - NCT05376878RecruitingPhase 4
PET/MRI scan to guide treatment in HER2+ brain metastatic breast cancer
This trial tests a special PET/MRI imaging scan using a labeled drug to help doctors evaluate HER2+ breast cancer that has spread to the brain. It focuses on patients who plan to receive fam-trastuzumab deruxtecan, a targeted cancer medicine, and aims to see how well the scan can support treatment decisions.
Duarte, CaliforniaAges 18 years+ - NCT05400941Enrolling by invitation
Breast cancer follow-up support in primary care
This study looks at how breast cancer follow-up care can be better done in primary care clinics. It may help by improving care check-ins and support for people who have had breast cancer and for clinic staff involved in that care.
New Brunswick, New JerseyAges 21 years+ - NCT05388149RecruitingPhase 2
Neratinib plus Kadcyla to treat leftover HER2 breast cancer
This trial studies whether adding neratinib to Kadcyla (T-DM1) can help eliminate “molecular residual disease,” meaning tiny traces of cancer left after surgery and standard HER2 treatment. It’s for adults with HER2-positive breast cancer who still test positive after a short course of Kadcyla, with no signs of cancer returning or spreading on scans.
Toronto, OntarioAges 18 years+ - NCT05404321Recruiting
Collecting tumor samples to study triple-negative breast cancer treatments
This study collects tumor tissue from people with early-stage triple-negative breast cancer before they start neoadjuvant chemotherapy. The goal is to help researchers test new therapies and look for markers that may predict who benefits.
CaenAges 18 years+ - NCT05386719Recruiting
Cardiometabolic screening for people after early breast cancer
This trial tests a screening program to look for heart- and metabolism-related health risks in people who have completed treatment for early breast cancer. It may help catch problems earlier so you can get timely care.
Baltimore, MarylandAges 18 years+ - NCT05403177Recruiting
Share your cancer data and samples for Ontario research
This study collects and combines medical records, genetic (genomic) data, and tumor/blood samples from people with cancer. It helps researchers build and improve a large “gold standard” cancer dataset that can support future studies and better understanding of cancer.
Kingston, OntarioAges 18 years+ - NCT05408117Recruiting
Compare suture types to reduce skin color changes after surgery
This study looks at whether different types of stitches (sutures) can lower the chance of pigment changes—skin color looking lighter or darker—after dermatology surgery. It may help patients who want to reduce the risk of visible skin color changes as their wound heals.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05378204Recruiting
Testing DNA repair marker for PARP inhibitor resistance
This study looks at specific DNA “damage repair” proteins as a marker to understand why some BRCA-mutated breast cancers may resist PARP inhibitor treatment. Your biopsy (or existing biopsy) helps researchers study whether these lab markers relate to how well PARP inhibitors work.
BordeauxAges 18 years+ - NCT05406232Recruiting
Radiation study to track immune changes in breast cancer
This study gives a short course of radiation to the breast or chest wall and measures how your immune system responds. It may help doctors better understand which immune changes happen after radiation and how this could improve palliative (symptom-relieving) care.
Houston, TexasAges 18 years+ - NCT05390515RecruitingPhase 4
Study immune response in adults with psoriasis on tildrakizumab
This trial studies how the immune system responds in adults with moderate-to-severe psoriasis when receiving tildrakizumab. The goal is to better understand treatment effects and immune changes, which may help improve care for people with psoriasis.
San Francisco, CaliforniaAges 18–75 - NCT05362929Recruiting
Laser treatment for acne scars in darker skin tones
This study tests a new type of laser treatment for acne scars in people with darker skin tones. It aims to see if the laser is effective and safe for improving the appearance of scars.
Elmsford, New YorkAges 18 years+ - NCT05364892Recruiting
Biobank study for ANCA-associated vasculitis patients
This study collects and stores health information and possibly samples from people diagnosed with ANCA-associated vasculitis to help researchers learn more about the disease. It may help future studies, but it is mainly focused on collection rather than testing a new treatment.
Brest, BrestAges 18–99 - NCT05412225RecruitingPhase 1
Pre-surgery radiation, then mastectomy and immediate breast reconstruction
This Phase 1 study looks at giving radiation before surgery for people with locally advanced breast cancer, then performing a mastectomy and immediate reconstruction. It aims to see whether this combined approach can shrink the cancer before surgery and safely allow reconstruction afterward.
Basking Ridge, New JerseyAges 18 years+ - NCT05399433Recruiting
Studying how sugar metabolism affects immune skin cells in psoriasis
This study looks at how blood sugar control (including diabetes) changes immune cells in the skin for people with moderate to severe plaque psoriasis. It may help researchers understand what drives psoriasis and how it could respond to future treatments.
Nice, Alpes-maritimesAges 18–80
Common questions
- How many skin clinical trials are recruiting?
- Clin2 is tracking 5,032 recruiting dermatology studies from the U.S. registry right now, out of 7,856 we cover in this area in total.
- What does “Skin” cover here?
- Psoriasis, eczema, skin cancers, and other conditions of the skin and connective tissue. We group each study into skin based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a skin trial near me?
- Use the search to filter skin studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.